Wang, Ding
Henry Ford Health · Henry Ford Hospital · NSABP Foundation
2 papers on CoChatORCID 0000-0002-4678-9954
Most cited papers
- Verified
Abstract CT032: A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies
Jimeno, A., Gupta, S., Sullivan, R., Do, K. T., Akerley, W. L., Wang, D., Teoh, D., Schalper, K., Zacharek, S. J., Sun, J., et al. (2020) · Cancer Research
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses
Cited by 41
- Verified
Neratinib-Plus-Cetuximab in Quadruple-WT ( KRAS, NRAS, BRAF, PIK3CA ) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Jacobs, S. A., Lee, J. J., George, T. J., Wade, J. L., Stella, P. J., Wang, D., Sama, A. R., Piette, F., Pogue-Geile, K. L., Kim, R. S., et al. (2021) · Clinical Cancer Research
Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research
Cited by 27
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free